ITCI - Intra-Cellular Therapies GAAP EPS of -$0.45 beats by $0.15 revenue of $87.87M beats by $0.9M
- Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q4 GAAP EPS of -$0.45 beats by $0.15 .
- Revenue of $87.87M (+242.3% Y/Y) beats by $0.9M .
- CEO comment: "We expect 2023 to be another year of significant growth for CAPLYTA and the company.”
- CAPLYTA 2023 net product sales are expected to be $430 to $455 million.
For further details see:
Intra-Cellular Therapies GAAP EPS of -$0.45 beats by $0.15, revenue of $87.87M beats by $0.9M